Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands		Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2016		4,363,346
Balance at Dec. 31, 2016		$ 1,818	$ 41,863	$ 51,713	$ (4,746)	$ (1,179)	$ 89,469
Net Income				6,944			6,944
Other Comprehensive Income (Loss)						58	58
Reclassification of the stranded tax effect related to deferred taxes for available-for-sale securities (1)	[1]			220		(220)
Restricted Stock Awards Granted			(142)		142
Stock-Based Compensation Expense			361				361
Exercise of Stock Options			7		24		31
Dividends Declared				(3,597)			(3,597)
Treasury Stock Purchased, at Cost					(10)		(10)
Dividends Declared				3,597			3,597
Treasury Stock Purchased, at Cost					10		10
Balance (in shares) at Dec. 31, 2017		4,363,346
Balance at Dec. 31, 2017		$ 1,818	42,089	55,280	(4,590)	(1,341)	93,256
Net Income				7,052			7,052
Other Comprehensive Income (Loss)						(59)	(59)
Restricted Stock Awards Granted			(329)		329
Stock-Based Compensation Expense			482				482
Exercise of Stock Options			5		208		213
Dividends Declared				4,529			4,529
Treasury Stock Purchased, at Cost					317		317
Issuance of Common Stock (net of issuance expenses of $515) (in shares)		1,317,647
Issuance of Common Stock (net of issuance expenses of $515)		$ 549	40,978				41,527
Dividends Declared				(4,529)			(4,529)
Treasury Stock Purchased, at Cost					(317)		(317)
Balance (in shares) at Dec. 31, 2018		5,680,993
Balance at Dec. 31, 2018		$ 2,367	83,225	57,843	(4,370)	(1,440)	137,625
Impact of change in method of accounting for marketable equity securities (2)	[2]			$ 40		$ (40)

[1] This reclassification is the result of the Company's early adopting of FASB ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220). See Note 1 for additional information.

[2] This reclassification is the result of the Company's adoption of FASB ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10). See Note 1 for additional information.